Rheumatoid arthritis: History, molecular mechanisms and therapeutic applications

A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics

Volumn , Issue , 2010, Pages 291-298

  Fishman, Pnina ^a   Bar Yehuda, Sara ^a  

^a Can Fite BioPharma   (Israel)

Author keywords

A3 adenosine receptor; CF101; human clinical studies; inflammatory cytokines; rheumatoid arthritis

Indexed keywords

EID: 79955618625     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-3144-0_15     Document Type: Chapter

References (39)

1. Albani S, Carson DA (1997) Etiology and pathogenesis of rheumatoid arthritis. In: Koopman WJ (ed) Arthritis and allied conditions. Lippincott Williams & Wilkins, Baltimore, MD, 979 p
2. 3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 32(3):469-476
3. 3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Inves Drugs 16(10):1601-1613
4. Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 1(11):529-543
5. Camussi G, Lupia E (1998) The future role of anti-tumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 55(5):613-620
6. Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, Baharav E (2006) The PI3K-NF-k B signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 8(1):1-9
7. Goldbach-Mansky R, Lipsky PE (2003) New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 54:197-216
8. Grassi W, De Angelis R, Lamanna G, Cervini C (1998) The clinical features of rheumatoid arthritis. Eur J Radiol 27(1):S18-S24
9. Grossman J, Brahn E (1997) Rheumatoid arthritis: current clinical and research directions. J Womens Health 6(6):627-638
10. Kavanaugh A, Lipsky PE (1996) Rheumatoid arthritis. In: Rich RR, Schwartz BD, Fleisher TA, Shearer WT, Strober W (eds) Clinical immunology: principles and practice. Mosby-Year Book, St Louis, MO, 1093 p
11. Kavanaugh A (2007) Current treatments for rheumatoid arthritis. Am J Orthop 236(3):4-7
12. Kirwan JR (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333(3):142-146
13. Lee D, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903-911
14. Lim SS, Conn DL (2001) The use of low-dose prednisone in the management of rheumatoid arthritis. Bull Rheum Dis 50(12):1-4
15. 3 adenosine receptor in PBMNC of rheumatoid arthritis patients: involvement of NF-kB in mediating receptor level. J Rheumatol 34(1):20-26
16. Majithia V, Geraci SA (2007) Rheumatoid arthritis: diagnosis and management. Am J Med 120(11):936-939
17. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D (2007) Macrophages in rheumatoid arthritis. Histol Histopathol 22(5):581-586
18. Matsuda Y, Yamanaka H, Higami K, Kashiwazaki S (1998) Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol 25(3):427-432
19. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S (2005) Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1(2):102-110
20. 3 adenosine receptor expression. Arthritis Res Ther 8(6):R169
21. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-?B signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant induced arthritis rats. Biochem Pharmacol 76(4):482-494
22. O'Dell J (2001) How is it best to treat early rheumatoid arthritis patients? Best Pract Res 15(1):125-137
23. Paleolog EM (2002) Angiogenesis in rheumatoid arthritis. Arthritis Res 4(3):S81-S90
24. Pap T, Müller-Ladner U, Gay RE, Gay S (2000) Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2(5):361-367
25. Plant M, Jones PW, Saklatvala J, Ollier WE, Dawes PT (1998) Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 25(3):417-426
26. 3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol 24(4):400-406
27. Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355(7):704-712
28. 3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 35(1):41-48
29. Sizova L (2008) Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br J Clin Pharmacol 66(2):173-178
30. Spargo LD, Cleland LG, Cockshell MP, Mayrhofer G (2006) Recruitment and proliferation of CD4+ T cells in synovium following adoptive transfer of adjuvant-induced arthritis. Int Immunol 18(6):897-910
31. Stoica BA, Movsesyan VA, Lea PM 4th, Faden AI (2003) Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol Cell Neurosci 22(3):365-382
32. Szabó C, Scott GS, Virág L, Egnaczyk G, Salzman AL, Shanley TP, Haskó G (1998) Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 125(2):379-387
33. Taurog JD, Sandberg GP, Mahowald ML (1983) The cellular basis of adjuvant arthritis. II. Characterization of the cells mediating passive transfer. Cell Immunol 80(1):198-204
34. 3 adenosine receptor agonists. J Med Chem 48(6):1745-1758
35. 3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 42(10):534-542
36. Varghese S (2006) Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front Biosci 1(11):2949-2966
37. Wang K, Scheel-Toellner D, Wong SH, Craddock R, Caamano J, Akbar AN, Salmon M, Lord JM (2003) Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phos-phoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J Immunol 171(2):1035-1041
38. Yang KY, Arcaroli J, Kupfner J, Pitts TM, Park JS, Strasshiem D, Perng RP, Abraham E (2003) Involvement of phosphatidylinositol 3-kinase gamma in neutrophil apoptosis. Cell Signal 15(2):225-233
39. 3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta 1500(3):280-290